Jason Brown
@JasonBrownMDPhD
Followers
459
Following
477
Media
73
Statuses
172
GU Oncologist at @UHhospitals
Cleveland, OH
Joined March 2010
Lots has happened in prostate cancer over the past year. 🎵 ARANOTE - darolutamide in mHSPC. ⚡️ AMPLITUDE - niraparib-abiraterone in mHSPC. 💦 SPLASH - 177LuPNT2002 in mCRPC. I discussed all this and more at the Case CCC ASCO Review today @caseccc @UHhospitals
0
0
9
Case CCC ASCO Review - @MosheOrnsteinMD dropping wisdom about bladder and kidney cancer @caseccc @ClevelandClinic @UHhospitals
0
0
11
RT @cwcheath: What a great day for service! @UHhospitals Seidman Cancer Center GU team volunteers with the @KidsBookBank ! . @PBarataMD .@J….
0
2
0
Results of AMPLITUDE study of abiraterone/prednisone/niraparib in metastatic hormone sensitive prostate cancer . ➕ Positive study. ⬇️ rPFS by almost 50 percent in BRCA1/2 patients. 🦴 Decreased time to symptomatic progression. 🧬 Genomic testing is critical!
0
0
3
Our own @angela_jia_ presenting her excellent insights into prostate cancer abstracts #ASCO25 @UHhospitals @caseccc
0
3
25
CtDNA exploratory analysis from NIAGARA by @tompowles1 #ASCO25. 👨🔬 CtDNA + decreased after neoadjuvant chemo and prior to cystectomy. 🧬 CtDNA - is favorable prognostic factor . 🧹 Better outcomes with CtDNA clearance than persistence. 🔪 CtDNA + post-cystectomy = poor prognosis
1
4
16
Witty discussion of frontline metastatic UC abstracts by @jackiebrown_MD #ASCO25. Many developments in this area since the platinum days and potentially changes to come with MIBC trials, de-escalation studies, and triplets under investigation
0
0
4
My @caseccc colleague @shilpaonc presenting analysis of responders from EV-302 #ASCO25 . ⬆️ Duration of response to EV/pembro amongst responders. 🩻 74% maintain CR at 2 years on EV/P. 💊 Median 12-13 cycles EV amongst responders. ❓ Can we de-escalate safely in EV/P responders?
0
1
7
SURE-02 trial of SG + pembro in MIBC presented by @AndreaNecchi #ASCO25 . 🔪 Included option for bladder preservation. 🔔 44% cCR, 100% metastasis free survival if cCR. 🧬 ERBB2 alt associated with response. MTAP loss with non-response
0
4
11
Tour de force discussion of results of CLONEVO IIT by @FaltasLab #ASCO25 . 💊 Abemaciclib with 31% downstaging rate is cis-ineligible MIBC. 🧬 CCND1 amp as biomarker of response. ⬇️ Ki-67 and pRB, meeting primary endpoint . 🔜 Use in conjunction with EV?
1
5
13
Gearing up for #ASCO25 this week!.
Jason Brown, MD, PhD @JasonBrownMDPhD shares real-world insights on immunotherapy biomarkers and trials like NP-G2-044. He’s also contributing to the METANOVA prostate cancer study on his poster @ASCO #ASCO2025.
0
2
11
Targeting HER2 in metastatic urothelial carcinoma: a contemporary review - Read on @degruyter_brill.
0
2
8
HER2 has emerged as an important target in mUC. We published this review article @AJangMD @caseccc @UHhospitals. 🧪 Testing methods: IHC (gastric scoring), NGS amplification. 💊 Targeting strategies: TKI, Ab, ADC. 🏁 Approval for T-DXd (IHC 3+), promising DV data.
1
2
9
RT @carisls: Can an immune response score with prognostic and predictive value in urothelial carcinoma be calculated from RNA expression da….
0
1
0
#GU25 Perioperative Trial w Disitimab Vedotin + Toripalimab. 🧪 HER2 positive (1+/2+/3+ IHC). ‼️ 63.6% pCR. 👏 92.5% 12 mo EFS. ⚡️ 21% peripheral neuropathy. 🗞️ HER2 is promising target . 🔜 With effective ADCs, bladder preservation studies needed. @OncoAlert @BladderCancerUS
1
8
21
#GU25 Updated NIAGARA results presented by @MattGalsky . 🎆 Continued EFS, OS benefit w perioperative Durvalumab + chemo. 🔎 Exploratory analysis: PFS & OS benefit in pts w pCR & non-pCR. ❓What is contribution of post-cystectomy durva, esp after pCR. @OncoAlert @BladderCancerUS
0
4
9
#GU25 Updates on checkmate 274 trial for adjuvant nivolumab presented by @MattMilowsky . 🚨 OS benefit in patients with MIBC (even greater with PD-L1 >= 1%. 🧪 Better DFS in patients without prior NAC. 🧬 Greater magnitude of DFS benefit w prior NAC. @OncoAlert @BladderCancerUS
0
6
11
TALAPRO2 - Talazoparib + Enza vs Placebo vs Enza #GU25 . 🔑 OS was key secondary endpoint. ☠️ 20% reduction of death (45 vs 37 months) in Tala/Enza arm in unselected patients. 🧬 HRR-deficient had greatest benefit but trend toward improved OS in non-HRR deficient subset
0
2
2
Prostatectomy vs Radiation for high risk prostate cancer presented by @UHhospitals upcoming faculty @Soum_Roy_RadOnc #GU25. 🧍♂️ Individual patient data from phase III RCT. ⬇️ Decreased risk of metastasis with XRT + ADT compared to prostatectomy. 🔜 Prospective trials needed
0
0
3